Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD9793 |
| Synonyms | |
| Therapy Description |
AZD9793 is a CD8-guided T-cell engager comprising a monoclonal trispecific antibody targeting GPC3, TCR, and CD8 co-receptor, which potentially induces cytolysis of GPC3-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD9793 | AZD-9793|AZD 9793 | GPC3 Antibody 7 | AZD9793 is a CD8-guided T-cell engager comprising a monoclonal trispecific antibody targeting GPC3, TCR, and CD8 co-receptor, which potentially induces cytolysis of GPC3-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06795022 | Phase Ib/II | AZD9793 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (RHEA-1) | Recruiting | USA | ESP | 5 |